Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial results will be released on Thursday, May 8, 2008, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time). Management will then host a conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss first quarter financial results and provide a corporate update.
To participate in the live conference call, U.S. residents should dial 800-638-5439 and international callers should dial 617-614-3945. The passcode for the live conference call is 67443467. To access the 24-hour telephone replay, U.S. residents should dial 888-286-8010 and international callers should dial 617-801-6888. The passcode for the replay is 97916996.
Alternatively, to access the live audio webcast for this conference call or the subsequent 30-day archive, please log on to Nastech’s Web site at http://www.nastech.com approximately 15 minutes prior to the conference call in order to register and download any necessary software.
Nastech is a clinical stage biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products based on its proprietary ribonucleic acid interference technology and proprietary molecular biology-based drug delivery technologies. Nastech and its collaboration partners are developing products for multiple therapeutic areas including diabetes, obesity, osteoporosis, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.
Nastech Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech or a subsidiary to obtain additional funding; (ii) the ability of Nastech or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Nastech, a subsidiary and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Nastech, a subsidiary and/or a partner to obtain required governmental approvals; and (v) the ability of Nastech, a subsidiary and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.